Celldex Therapeutics Inc. (TCE2)
XSTU 
Summary
TCE2 Chart
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.85 per share a year ago.
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
Celldex Therapeutics NASDAQ: CLDX said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the drug in that indication while continuing to focus on ongoing late-stage urticaria studies.
Celldex Therapeutics Inc. (TCE2) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Celldex Therapeutics Inc. ever had a stock split?
Celldex Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Anthony S. Marucci CEO | XSTU Exchange | 15117B202 CUSIP |
| US Country | 198 Employees | - Last Dividend | 10 Mar 2008 Last Split | 10 Mar 2008 IPO Date |
Overview
Celldex Therapeutics, Inc. is a pioneering biopharmaceutical company focused on the development and commercialization of innovative monoclonal and bispecific antibodies aimed at treating a wide range of diseases. With a focus on inflammatory, allergic, autoimmune, and other devastating diseases, the company leverages its scientific expertise to create therapies that can improve the lives of patients. Founded in 1983 and based in Hampton, New Jersey, Celldex Therapeutics has established itself as a leader in the field of antibody-based therapeutics. The company's commitment to addressing unmet medical needs through cutting-edge research and development is exemplified by its collaboration with prestigious institutions like Yale University. This strategic partnership underscores Celldex Therapeutics' dedication to advancing its pipeline of drug candidates through innovative research and development initiatives.
Products and Services
Celldex Therapeutics, Inc. is at the forefront of developing antibody-based therapeutics for a variety of diseases. Below are key candidates in their clinical development programs:
- CDX-0159: CDX-0159 is a Phase II monoclonal antibody that represents a significant advancement in the treatment of diseases mediated by the receptor tyrosine kinase KIT. By binding to KIT and inhibiting its activity, CDX-0159 has the potential to offer therapeutic benefits in conditions where KIT plays a pivotal role. This could include a range of inflammatory, allergic, and autoimmune diseases, showcasing the versatility and therapeutic potential of Celldex’s antibody technology.
The company’s rigorous focus on research and development within the monoclonal and bispecific antibody space illustrates its commitment to pioneering new treatments that can offer hope to patients with severe and life-threatening conditions. Through its productive research collaboration and license agreements, notably with Yale University, Celldex Therapeutics ensures a continuous flow of innovation and expertise into its development programs, further strengthening its product pipeline.
